---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-137922"
form_type: "8-K"
ticker: "AKTX"
cik: "0001541157"
company_name: "Akari Therapeutics Plc"
filed_at: "2024-12-18T23:59:59+00:00"
generated_at: "2026-05-29T01:59:03.072168+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Akari Therapeutics appoints Samir R. Patel as permanent CEO, adds Abizer Gaslightwala to board

## Summary
- Dr. Samir R. Patel appointed CEO effective Dec 16, 2024; he served as interim CEO since May 2024.
- Abizer Gaslightwala appointed as Class A director effective Dec 16, 2024; term expires at 2025 AGM.
- Michael Grissinger resigned from board on Dec 16, 2024; no disagreement with company operations.
- Gaslightwala is SVP at Jazz Pharma, previously at Amgen and Pfizer; deemed independent under Nasdaq rules.

## SEC filing metadata
- accession: 0000950170-24-137922
- form_type: 8-K
- ticker: AKTX
- cik: 0001541157
- company_name: Akari Therapeutics Plc
- filed_at: 2024-12-18T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1541157/000095017024137922/0000950170-24-137922-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1541157/000095017024137922/aktx-20241212.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-137922
- JSON: https://secwatch.observer/filing/0000950170-24-137922.json
- Plain text: https://secwatch.observer/filing/0000950170-24-137922.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.